Abstracts tagged "complement"

Abstract Number: 0578 • ACR Convergence 2023
Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis
Meghan Anderson¹, Cynthia Magro² and H Michael Belmont³, ¹New York University, New York, NY, ²Weill Cornell Medicine, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Tissue damage in LN is mediated by immune complex activation of the classic complement pathway (PMID 23929771). In a study of LN, renal C5b-9…
Abstract Number: 2311 • ACR Convergence 2023
Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene
Ani Oganesyan¹, Rachel Sharp², Philip O’Neill³, Cynthia Aranow⁴, Laurent Arnaud⁵, Anca Askanase⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Ian Bruce⁹, Jill Buyon¹⁰, Winn Chatham¹¹, Ann Clarke¹², Nathalie Costedoat-Chalumeau¹³, Mary Anne Dooley¹⁴, Paul R. Fortin¹⁵, Ellen Ginzler¹⁶, Dafna Gladman¹⁷, Caroline Gordon¹⁸, John G. Hanly¹⁹, Murat Inanç²⁰, David Isenberg²¹, Soren Jacobsen²², Andreas Jonsen²³, Kenneth Kalunian²⁴, Diane L. Kamen²⁵, S. Sam Lim²⁶, Anselm Mak²⁷, Eric Morand²⁸, Christine Peschken²⁹, Michelle Petri³⁰, Bernando A. Pons-Estel³¹, Anisur Rahman³², Rosalind Ramsey-Goldman³³, John Reynolds³⁴, Juanita Romero-Diaz³⁵, Guillermo Ruiz-Irastorza³⁶, Jorge Sanchez-Guerrero³⁷, Kristjan Steinsson³⁸, Murray Urowitz³⁹, Ronald van Vollenhoven⁴⁰, Evelyne Vinet⁴¹, Alexandre Voskuyl⁴², Daniel Wallace⁴³, Susan Manzi⁴⁴, Kenneth L. Jones⁴⁵ and Susan A. Boackle⁴⁶, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶Columbia University Medical Center, New York, NY, ⁷Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹University of Manchester, Manchester, United Kingdom, ¹⁰NYU Grossman School of Medicine, New York, NY, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹³Inserm DR Paris 5, Paris, France, ¹⁴Raleigh Neurology Associates, Chapel Hill, NC, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁶SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁸Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁹Dalhousie University, Halifax, NS, Canada, ²⁰Istanbul University, Istanbul, Turkey, ²¹University College London, London, United Kingdom, ²²Rigshospitalet, Copenhagen, Denmark, ²³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²⁴University of California San Diego, La Jolla, CA, ²⁵Medical University of South Carolina, Charleston, SC, ²⁶Emory University, Atlanta, GA, ²⁷Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²⁸Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²⁹University of Manitoba, Winnipeg, MB, Canada, ³⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ³¹Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ³²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³³Northwestern University, Chicago, IL, ³⁴University of Birmingham, Birmingham, United Kingdom, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³⁶Hospital Universitario Cruces, Barakaldo, Spain, ³⁷University Health Network, Toronto, ON, Canada, ³⁸Landspitali University Hospital, Reykjavik, Iceland, ³⁹Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴⁰Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴¹McGill University Health Centre, Montréal, QC, Canada, ⁴²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁴⁵Bioinformatics Solutions, Sheridan, WY, ⁴⁶None, Denver, CO
Background/Purpose: Systemic lupus erythematosus is a heterogenous autoimmune disease characterized by inflammatory damage to multiple organ systems. We have shown that the single-nucleotide polymorphism (SNP)…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 2327 • ACR Convergence 2023
Hydroxychloroquine Improves Low Complement Levels
Michelle Petri¹, Rebecca Jacobson², Andrea Fava³ and Larry Magder⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Low complement is associated with clinical disease activity and future organ damage in patients with systemic lupus erythematosus (SLE). Prior studies from Japan, although…
Abstract Number: 0683 • ACR Convergence 2023
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Duvuru Geetha¹, Frank Cortazar², Annette Bruchfeld³, alexandre Karras⁴, Peter Merkel⁵ and David Jayne⁶, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³Karolinska Institutet, Stockholm, Sweden, ⁴HEGP - APHP, Paris, France, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the Phase 3 ADVOCATE trial comparing avacopan to a prednisone taper, 81% of patients with ANCA-associated vasculitis (AAV) had renal involvement based on…
Abstract Number: 2338 • ACR Convergence 2023
Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
Maria Dall'Era¹, Juan Lichauco², Hsiang Chen³, Harold Gomez⁴, Michael Tee⁵, Caroline Arroyo⁶, Joung-Liang Lan⁷, Yao-Fan Fang⁸, Edmund Chang⁹, Noosha Yousefpour⁹, Julian Low⁹, Min Bao⁹, Qing Chang⁹, Jeannette Osterloh⁹, Ann Mongan⁹, Ted Yednock⁹, Dean Artis⁹, Yaisa Andrews-Zwilling⁹ and Henk-Andre Kroon⁹, ¹University of California San Francisco, San Francisco, CA, ²St. Luke’s Medical Center, Quezon City, Philippines, ³Tri-service General Hospital, Taipei City, Taiwan, ⁴Angeles University Foundation Medical Center, Pampanga, Philippines, ⁵Medical Center Manila and University of the Philippines Manila, Manila, Philippines, ⁶Iloilo Doctors Hospital, Iloilo City, Philippines, ⁷China Medical University Hospital, Taichung, Taiwan, ⁸Chang Gung Memorial Hospital, Linkou, Taiwan, ⁹Annexon Biosciences, Brisbane, CA
Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease involving glomerular deposition of immune complexes containing pathogenic anti-C1q antibodies, leading to C1q binding and activation of…
Abstract Number: 0684 • ACR Convergence 2023
Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Ulrich Specks¹, David Jayne² and Peter Merkel³, ¹Mayo Clinic, Rochester, MN, ²University of Cambridge, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
Abstract Number: 2370 • ACR Convergence 2023
C5 as a Genetic Marker for Discriminating Between IgA Vasculitis and IgA Nephropathy?
JOAO CARLOS BATISTA LIZ¹, Vanesa Calvo Río², María Sebastián Mora-Gil¹, Belén Sevilla-Pérez³, María Teresa Leonardo⁴, Ana Peñalba⁴, María Jesús Cabero⁴, Javier Narvaez⁵, luis martin penagos⁶, Emilio Rodrigo⁶, Lara Belmar-Vega⁶, Cristina Gomez-Fernandez⁷, Luis Caminal-Montero⁸, Paz Collado⁹, Antonio Fernandez-Nebro¹⁰, gisela Díaz-Cordovés¹¹, Maryia Nikitsina¹², Esther Vicente Rabaneda¹³, secundino Cigarrán¹⁴, jesús Calviño¹⁵, carmen cobelo¹⁵, Manuel León Luque¹⁶, Esteban Rubio¹⁶, Juan María Blanco-Madrigal¹⁷, Eva Galindez-Agirregoikoa¹⁸, Santos Castañeda¹⁹, Ricardo Blanco²⁰, Verónica Pulito-Cueto¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁷Division of Dermatology,Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁸Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ⁹Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹⁰Hospital Regional Universitario de Málaga, Malaga, Spain, ¹¹Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Nephrology, Hospital da Costa Burela, Lugo, Spain, ¹⁵Division of Nephrology, Hospital Universitario Lucus Augusti, Lugo, Spain, ¹⁶Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁷Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁸Basurto University Hospital, Bilbao, Spain, ¹⁹Hospital Universitario de la Princesa, Madrid, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Immunoglobulin-A vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathophysiological mechanisms1,2. Similar features are also described between IgAV nephritis (IgAVN) and…
Abstract Number: 1135 • ACR Convergence 2022
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, Anna Broder², Daming Shao³, Vartika Kesarwani⁴, Brianna Lally⁵, Masako Suzuki⁶, J. Michelle Kahlenberg⁷, Jennifer Aguilan⁶ and Simone Sidoli⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Hackensack University Medical Center, Hackensack, NJ, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴University of Connecticut, Farmington, CT, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Anne Troldborg¹, Mads Lamm Larsen¹, Erik J.M. Toonen², Lisa Hurler³, Zoltan Prohaszka³, László Cervenak³, Annette Gudmann Hansen⁴ and Steffen Thiel⁴, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Hycult Biotech, Arnhem-Nijmegen, Netherlands, ³Semmelweis University, Budapest, Hungary, ⁴Aarhus University, Aarhus, Denmark
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
Abstract Number: 1733 • ACR Convergence 2022
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Jonsson¹, Carlos Donado², Emma Gomez-Rivas¹ and Michael Brenner³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. Most research has focused on CD4 T cells, but we have found that CD8+…
Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Marcela Muñoz Urbano¹, Diana C. Quintero-González¹, Mauricio Rojas², Joaquín Rodelo¹, Alba Luz León Álvarez¹, Luis Gonzalez¹ and Gloria Vásquez³, ¹Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
Abstract Number: 0144 • ACR Convergence 2022
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
Guy Katz¹, Amelia S. Cogan¹, Grace McMahon¹, Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹, John Atkinson², Alfred Kim² and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Washington University School of Medicine, St. Louis, MO, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
Abstract Number: 0317 • ACR Convergence 2022
Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression
Ivan Ferraz Amaro¹, maría García-González², carmen Ferrer-Moure², Fuensanta Gómez-Bernal², Antonia De Vera-González², Alejandra González Delgado², Agustín Francisco González-Rivero², Yolanda Fernández-Cladera², Juan Carlos Quevedo Abeledo³ and Federico Díaz-González⁴, ¹Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife
Background/Purpose: Activation of the classical complement (C) pathway by immune complexes is a characteristic of patients with systemic lupus erythematosus (SLE). Accelerated consumption outstrips synthesis…

« Previous Page
1
…
3
4
5
6
7
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].